Fate Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
June 10, 2020 8:16 AM EDTOppenheimer analyst Matthew Biegler raised the price target on Fate Therapeutics (NASDAQ: FATE) to $40.00 (from $34.00) while maintaining a Outperform rating following the company's update on its iPSC-derived cell therapy programs in conjunction with an equity financing. The update included preliminary data from the first... More
Fate Therapeutics (FATE) PT Raised to $45 at Guggenheim
June 10, 2020 7:51 AM EDTGuggenheim analyst Michael Schmidt raised the price target on Fate Therapeutics (NASDAQ: FATE) to $45.00 (from $43.00) while maintaining a Buy rating after the company provided a portfolio-wide clinical update. The update was part of the SEC filings for FATE's capital raise.
Guggenheim... More
